Update: 27 September 2019
No update available
Update: 30 July 2019
Results announced during 24th Annual Congress of the European Hematology Association show that treatment with single and multiple oral doses of VIT-2763 were well tolerated in healthy subjects, decreasing the iron levels in circulation.
A proof of concept study in patients with β-thalassaemia is supported by these results.
Update: 30 May 2019
No update available.
Update: 01 February 2019
A randomized, controlled, multi-centred phase 2 proof-of-concept trial will begin in the second half of 2019 to assess the effectiveness of the oral ferroportin inhibitor (VIT-2763) on iron overload in β-thalassaemia patients.
Phase 1 trials have shown positive results with a consistent lower serum iron for up to 24 hours post-dose. The results are dose-dependent.
Treatment with VIT-2763 can improve iron metabolism and the production of RBCs.